WealthyVC.com scans North America’s 10,000+ publicly listed stocks across all seven exchanges to find the market-moving news that matters. Our focus is on quality, liquid, growth-oriented companies in...
There are few things in the investment world scarier than owning a biotech that misses the mark. That was the case this morning with once high-flying stock Cassava Sciences (SAVA). This is a stock that...
D. Boral Capital believes Anavex’s Alzheimer’s treatment is superior to Cassava Sciences' approach.
The CEO noted that the findings also impact the company’s second Phase 3 trial, ReFocus-ALZ, which has now been discontinued alongside an Open Label Extension study.
Cassava Sciences appoints Freda Nassif as Chief Commercial Officer, enhancing its strategy ahead of Phase 3 trial results for Alzheimer's treatment.Quiver AI SummaryCassava Sciences has appointed Freda...
Alzheimer’s Drug Market Faces Urgent Need for Innovative Therapies Beyond Big Pharma These Small-Cap Biotech Stocks Lead the Charge with Disruptive Approaches to Treating Alzheimer’s Alzheimer’s...